CJC-1295 + Ipamorelin

This combination pairs two complementary growth hormone secretagogues: CJC-1295 and Ipamorelin. CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), while Ipamorelin is a selective growth hormone secretagogue receptor (GHSR) agonist.

The combination works synergistically through different mechanisms. CJC-1295 extends the duration of growth hormone release by protecting against enzymatic degradation, while Ipamorelin stimulates pulsatile growth hormone secretion through ghrelin receptor activation. Together, they produce a more robust and sustained growth hormone response than either peptide alone.

Research has shown that this combination can support increased growth hormone levels, which may have effects on body composition, recovery, sleep quality, and overall vitality. The peptides are selective, meaning they primarily affect growth hormone without significantly impacting cortisol or prolactin levels.

Both peptides have favorable safety profiles in research settings, with Ipamorelin being particularly noted for its selectivity and minimal side effects compared to older secretagogues.